P4HB x STING

评价TSN222治疗晚期实体瘤或淋巴瘤受试者的安全性和耐受性，确定最大耐受剂量（MTD）和/或II期推荐剂量RP2D(s) 评估TSN222及其代谢产物的药代动力学（PK）特征 评估TSN222治疗晚期实体瘤或淋巴瘤的初步疗效

The study is a first-in-human [FIH], open-label phase 1/2 study of TSN222 in subjects with advanced solid tumors or lymphomas. This study is comprised of a Phase 1 dose escalation and Phase 2 dose expansion component.